Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 13, 2021 Filed Apr 15, 2021 20:52 UTC |
Peraza LisaVP, Chief Accounting Officer
|
Exercise / conversionCommon Stock | 552 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-026842 · doc4.xml · nonDerivative · entry 1 Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:51 UTC |
MANHARD KIMBERLYDirector · EVP, Drug Development
|
Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-026841 · doc4.xml · derivative · entry 3 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:51 UTC |
MANHARD KIMBERLYDirector · EVP, Drug Development
|
Tax withholdingCommon Stock | 433 | $16.66 | $7,213.78 |
DisclosureSEC source: 0001209191-21-026841 · doc4.xml · nonDerivative · entry 2 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,634 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:51 UTC |
MANHARD KIMBERLYDirector · EVP, Drug Development
|
Exercise / conversionCommon Stock | 1,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-026841 · doc4.xml · nonDerivative · entry 1 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,067 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| April 06, 2021 Filed Apr 7, 2021 21:04 UTC |
Johnson Craig ADirector
|
SaleCommon Stock | 250 | $17.22 | $4,305.20 |
DisclosureSEC source: 0001209191-21-025903 · doc4.xml · nonDerivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,590 F1 · kind: The sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of March 3, 2021. F2 · price: The range of sales prices received was $16.98 to $17.48. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
| January 14, 2021 Filed Jan 15, 2021 21:30 UTC |
Szekeres David LeslieEVP, Chief Operating Officer
|
SaleCommon Stock | 827 | $18.09 | $14,960.18 |
DisclosureSEC source: 0001209191-21-003807 · doc4.xml · nonDerivative · entry 3 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · kind: The sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of November 30, 2020. F4 · price: The range of sales prices received was $17.71 to $18.40. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:30 UTC |
Szekeres David LeslieEVP, Chief Operating Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-003807 · doc4.xml · derivative · entry 4 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). F5 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:30 UTC |
Szekeres David LeslieEVP, Chief Operating Officer
|
Tax withholdingCommon Stock | 423 | $18.16 | $7,681.68 |
DisclosureSEC source: 0001209191-21-003807 · doc4.xml · nonDerivative · entry 2 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 827 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:30 UTC |
Szekeres David LeslieEVP, Chief Operating Officer
|
Exercise / conversionCommon Stock | 1,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-003807 · doc4.xml · nonDerivative · entry 1 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:29 UTC |
Quart Barry DDirector · Chief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 3,646 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-003804 · doc4.xml · derivative · entry 3 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,687 Underlying: Common Stock · 3,646 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:29 UTC |
Quart Barry DDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 963 | $18.16 | $17,488.08 |
DisclosureSEC source: 0001209191-21-003804 · doc4.xml · nonDerivative · entry 2 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,909 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:29 UTC |
Quart Barry DDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 3,646 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-003804 · doc4.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:27 UTC |
POYHONEN JOHNPresident & CCO
|
Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-003798 · doc4.xml · derivative · entry 3 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:27 UTC |
POYHONEN JOHNPresident & CCO
|
Tax withholdingCommon Stock | 433 | $18.16 | $7,863.28 |
DisclosureSEC source: 0001209191-21-003798 · doc4.xml · nonDerivative · entry 2 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,597 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:27 UTC |
POYHONEN JOHNPresident & CCO
|
Exercise / conversionCommon Stock | 1,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-003798 · doc4.xml · nonDerivative · entry 1 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:26 UTC |
Peraza LisaVP, Chief Accounting Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 552 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-003794 · doc4.xml · derivative · entry 3 Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,281 Underlying: Common Stock · 552 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:26 UTC |
Peraza LisaVP, Chief Accounting Officer
|
Tax withholdingCommon Stock | 227 | $18.16 | $4,122.32 |
DisclosureSEC source: 0001209191-21-003794 · doc4.xml · nonDerivative · entry 2 Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,584 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:26 UTC |
Peraza LisaVP, Chief Accounting Officer
|
Exercise / conversionCommon Stock | 552 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-003794 · doc4.xml · nonDerivative · entry 1 Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:25 UTC |
MANHARD KIMBERLYDirector · EVP, Drug Development
|
Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-003788 · doc4.xml · derivative · entry 3 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:25 UTC |
MANHARD KIMBERLYDirector · EVP, Drug Development
|
Tax withholdingCommon Stock | 433 | $18.16 | $7,863.28 |
DisclosureSEC source: 0001209191-21-003788 · doc4.xml · nonDerivative · entry 2 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 817 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:25 UTC |
MANHARD KIMBERLYDirector · EVP, Drug Development
|
Exercise / conversionCommon Stock | 1,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-003788 · doc4.xml · nonDerivative · entry 1 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 08, 2021 Filed Jan 8, 2021 23:07 UTC |
Szekeres David LeslieEVP, Chief Operating Officer
|
SaleCommon Stock | 3,571 | $19.66 | $70,219.43 |
DisclosureSEC source: 0001209191-21-002806 · doc4.xml · nonDerivative · entry 1 Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of November 30, 2020. F2 · price: The range of sales prices received was $19.45 to $19.94. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 21:23 UTC |
MANHARD KIMBERLYDirector · EVP, Drug Development
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0001209191-20-065014 · doc4.xml · derivative · entry 3 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,416 Underlying: Common Stock · 10,000 shares Expires 2026-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of September 15, 2020. F2 · derivative.exercise_date: The stock option vested and became exercisable in 48 equal monthly installments beginning one month after the date of grant (12/21/2016). Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 21:23 UTC |
MANHARD KIMBERLYDirector · EVP, Drug Development
|
SaleCommon Stock | 10,000 | $20.00 | $200,000.00 |
DisclosureSEC source: 0001209191-20-065014 · doc4.xml · nonDerivative · entry 2 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of September 15, 2020. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 21:23 UTC |
MANHARD KIMBERLYDirector · EVP, Drug Development
|
Exercise / conversionCommon Stock | 10,000 | $13.00 | $130,000.00 |
DisclosureSEC source: 0001209191-20-065014 · doc4.xml · nonDerivative · entry 1 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of September 15, 2020. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:21 UTC |
Christian WaageDirector
|
GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $19.46 | $0.00 |
DisclosureSEC source: 0001209191-20-065012 · doc4.xml · derivative · entry 2 Christian Waage · CIK 0001553179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2030-12-21 F2 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:21 UTC |
Christian WaageDirector
|
GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-065012 · doc4.xml · nonDerivative · entry 1 Christian Waage · CIK 0001553179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,400 F1 · shares: The shares were granted as restricted stock units which vest in four equal quarterly installments beginning three months after the date of grant. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:20 UTC |
DAVIS STEPHENDirector
|
GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $19.46 | $0.00 |
DisclosureSEC source: 0001209191-20-065009 · doc4.xml · derivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2030-12-21 F2 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:20 UTC |
DAVIS STEPHENDirector
|
GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-065009 · doc4.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · shares: The shares were granted as restricted stock units which vest in four equal quarterly installments beginning three months after the date of grant. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:21 UTC |
Johnson Craig ADirector
|
GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $19.46 | $0.00 |
DisclosureSEC source: 0001209191-20-065011 · doc4.xml · derivative · entry 2 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2030-12-21 F2 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:21 UTC |
Johnson Craig ADirector
|
GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-065011 · doc4.xml · nonDerivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,840 F1 · shares: The shares were granted as restricted stock units which vest in four equal quarterly installments beginning three months after the date of grant. Read SEC document |
| October 30, 2020 Filed Dec 23, 2020 21:24 UTC |
POYHONEN JOHNPresident & CCO
|
OtherCommon Stock | 637 | $11.65 | $7,423.28 |
DisclosureSEC source: 0001209191-20-065016 · doc4.xml · nonDerivative · entry 1 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,780 F1 · kind: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on October 30, 2020. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 20:35 UTC |
Peraza LisaVP, Chief Accounting Officer
|
GrantRestricted Stock Units · Derivative | 8,833 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-054914 · doc4.xml · derivative · entry 2 Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,833 Underlying: Common Stock · 8,833 shares Expires not disclosed F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant. F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 20:35 UTC |
Peraza LisaVP, Chief Accounting Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 103,000 | $0.00 Strike: $15.72 | $0.00 |
DisclosureSEC source: 0001209191-20-054914 · doc4.xml · derivative · entry 1 Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,000 Underlying: Common Stock · 103,000 shares Expires 2030-10-13 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 20:25 UTC |
MANHARD KIMBERLYDirector · EVP, Drug Development
|
GrantRestricted Stock Units · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-054909 · doc4.xml · derivative · entry 2 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant. F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 20:25 UTC |
MANHARD KIMBERLYDirector · EVP, Drug Development
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $15.72 | $0.00 |
DisclosureSEC source: 0001209191-20-054909 · doc4.xml · derivative · entry 1 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2030-10-13 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 20:24 UTC |
POYHONEN JOHNPresident & CCO
|
GrantRestricted Stock Units · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-054908 · doc4.xml · derivative · entry 2 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant. F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 20:24 UTC |
POYHONEN JOHNPresident & CCO
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 170,000 | $0.00 Strike: $15.72 | $0.00 |
DisclosureSEC source: 0001209191-20-054908 · doc4.xml · derivative · entry 1 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2030-10-13 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 20:23 UTC |
Quart Barry DDirector · Chief Executive Officer
|
GrantRestricted Stock Units · Derivative | 58,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-054907 · doc4.xml · derivative · entry 3 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,333 Underlying: Common Stock · 58,333 shares Expires not disclosed F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant. F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 20:23 UTC |
Quart Barry DDirector · Chief Executive Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $15.72 | $0.00 |
DisclosureSEC source: 0001209191-20-054907 · doc4.xml · derivative · entry 2 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2030-10-13 F2 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 20:21 UTC |
Christian WaageDirector
|
GrantStock Option (Right to Buy) · Derivative | 437 | $0.00 Strike: $15.72 | $0.00 |
DisclosureSEC source: 0001209191-20-054906 · doc4.xml · derivative · entry 1 Christian Waage · CIK 0001553179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 437 Underlying: Common Stock · 437 shares Expires 2030-10-13 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in two equal monthly installments beginning one month after the date of grant. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 20:20 UTC |
DAVIS STEPHENDirector
|
GrantStock Option (Right to Buy) · Derivative | 765 | $0.00 Strike: $15.72 | $0.00 |
DisclosureSEC source: 0001209191-20-054905 · doc4.xml · derivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 765 Underlying: Common Stock · 765 shares Expires 2030-10-13 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in two equal monthly installments beginning one month after the date of grant. Read SEC document |
| May 01, 2020 Filed May 1, 2020 22:48 UTC |
MANHARD KIMBERLYDirector · Executive VP, Drug Development
|
SaleCommon Stock | 1,158 | $13.97 | $16,175.75 |
DisclosureSEC source: 0001209191-20-026627 · doc4.xml · nonDerivative · entry 2 MANHARD KIMBERLY · CIK 0001202094 · Director · Executive VP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: The sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of June 13, 2019. F3 · price: The range of sales prices received was $13.91 to $14.06. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
| April 30, 2020 Filed May 1, 2020 22:48 UTC |
MANHARD KIMBERLYDirector · Executive VP, Drug Development
|
OtherCommon Stock | 1,158 | $12.12 | $14,036.12 |
DisclosureSEC source: 0001209191-20-026627 · doc4.xml · nonDerivative · entry 1 MANHARD KIMBERLY · CIK 0001202094 · Director · Executive VP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,158 F1 · kind: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2020. Read SEC document |
| April 30, 2020 Filed Oct 15, 2020 20:23 UTC |
Quart Barry DDirector · Chief Executive Officer
|
OtherCommon Stock | 1,158 | $12.12 | $14,036.12 |
DisclosureSEC source: 0001209191-20-054907 · doc4.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,226 F1 · kind: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2020. Read SEC document |
| April 15, 2020 Filed Apr 18, 2020 01:08 UTC |
Christian WaageDirector
|
GrantStock Option (Right to Buy) · Derivative | 713 | $0.00 Strike: $14.44 | $0.00 |
DisclosureSEC source: 0001209191-20-025021 · doc4.xml · derivative · entry 1 Christian Waage · CIK 0001553179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 713 Underlying: Common Stock · 713 shares Expires 2030-04-15 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in eight equal monthly installments beginning one month after the date of grant. Read SEC document |
| April 15, 2020 Filed Apr 18, 2020 01:07 UTC |
DAVIS STEPHENDirector
|
GrantStock Option (Right to Buy) · Derivative | 1,426 | $0.00 Strike: $14.44 | $0.00 |
DisclosureSEC source: 0001209191-20-025019 · doc4.xml · derivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,426 Underlying: Common Stock · 1,426 shares Expires 2030-04-15 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in eight equal monthly installments beginning one month after the date of grant. Read SEC document |
| January 07, 2020 Filed Feb 16, 2021 21:18 UTC |
TANG KEVINFormer Director
|
GiftCommon Stock | 520,299 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-010719 · doc5.xml · nonDerivative · entry 2 TANG KEVIN C · CIK 0001178579 · Former Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 0 F1 · kind: The gifted securities were held by Tang Capital Partners, LP and were donated to a charitable organization. F2 · ownership.direct: The securities were held by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The securities were held by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| January 06, 2020 Filed Feb 16, 2021 21:18 UTC |
TANG KEVINFormer Director
|
GiftCommon Stock | 1,600,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-010719 · doc5.xml · nonDerivative · entry 1 TANG KEVIN C · CIK 0001178579 · Former Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 0 F1 · kind: The gifted securities were held by Tang Capital Partners, LP and were donated to a charitable organization. F2 · ownership.direct: The securities were held by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The securities were held by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| December 31, 2019 Filed Feb 14, 2020 21:02 UTC |
TANG KEVINDirector
|
GiftCommon Stock | 297,714 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-009590 · doc5.xml · nonDerivative · entry 9 TANG KEVIN C · CIK 0001178579 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 5,017,203 F1 · kind: The gifted securities were held by Tang Capital Partners, LP and were donated to charitable organizations. F2 · ownership.direct: The securities are held by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The securities are held by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.